Literature DB >> 19338096

Cytotoxic responses to alloantigens in systemic lupus erythematosus.

G C Tsokos1, J E Balow.   

Abstract

We have studied the ability of the peripheral mononuclear cells (MNC) from patients with systemic lupus erythematosus (SLE) to generate a cytotoxic (CML) response against alloantigens. CML responses in SLE patients were significantly lower than those of normal individuals. Mixed lymphocyte reaction (MLR) assays conducted in parallel in these patients were decreased but to a lesser extent. Some of the patients exhibited parallel decreases in both CML and MLR tests, while others showed decreased CML responses but normal MLR responses. Optimal CML responses in SLE patients did not occur at a different time point than in the normals. Plasma from most SLE patients tested did not have an effect on CML and MLR responses of normal MNC; the plasma of only one patient consistently decreased the CML of normal cells. Depletion of adherent cells from MNC of SLE patients by Sephadex G-10 fractionation allowed better CML and MLR responses. Low CML responses in patients with SLE were associated with increased disease activity and increased serum DNA binding. No association between MLR responses in SLE patients and any of the above parameters was detected. SLE patients not having received any cytotoxic treatment exhibited the lowest CML responses, while these under treatment or treated in the past had higher, although not normal, responses. MLR responses were not affected by the treatment status of the patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19338096     DOI: 10.1007/bf00915138

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  53 in total

1.  B-lymphocyte alloantigens associated with systemic lupus erythematosus.

Authors:  J L Reinertsen; J H Klippel; A H Johnson; A D Steinberg; J L Decker; D L Mann
Journal:  N Engl J Med       Date:  1978-09-07       Impact factor: 91.245

2.  Cell-mediated immunity in systemic lupus erythematosus.

Authors:  A A Andrianakos; P N Tsichlis; E G Merikas; S G Marketos; J T Sharp; G E Merikas
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

3.  Immune function in systemic lupus erythematosus. Impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen.

Authors:  A B Gottlieb; R G Lahita; N Chiorazzi; H G Kunkel
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

4.  PHA-induced cellular cytotoxicity. Inhibition by a nonimmunoglobulin factor present in sera from patients with active systemic lupus erythematosus.

Authors:  A Ruíz-Argüelles; E Díaz-Jouanen; D Alarcón-Segovia
Journal:  Arthritis Rheum       Date:  1979-01

5.  Studies of immune functions of patients with systemic lupus erythematosus. T-cell subsets and antibodies to T-cell subsets.

Authors:  T Sakane; A D Steinberg; J P Reeves; I Green
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

6.  Suppressor cell defect in SLE: relationship to native DNA binding.

Authors:  R S Krakauer; J D Clough; T Alexander; J Sundeen; D N Sauder
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

7.  Natural killer funciton in systemic lupus erythematosus.

Authors:  T Hoffman
Journal:  Arthritis Rheum       Date:  1980-01

8.  Serum effects of mitogenic reactivity in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Technical considerations and lack of correlation with anti-lymphocyte antibodies.

Authors:  D A Horwitz; M A Garrett; A H Craig
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

9.  Heterogeneity in the development of cytotoxic T lymphocytes in vitro revealed by sensitivity to hydrocortisone.

Authors:  A Altman; I R Cohen
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

10.  Antibodies to a specific surface antigen of T cells in human sera inhibiting mixed leukocyte culture reactions.

Authors:  P Wernet; H G Kunkel
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

View more
  5 in total

1.  IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells.

Authors:  Masayuki Mizui; Tomohiro Koga; Linda A Lieberman; Jessica Beltran; Nobuya Yoshida; Mark C Johnson; Roland Tisch; George C Tsokos
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

2.  Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity.

Authors:  A Shustov; I Luzina; P Nguyen; J C Papadimitriou; B Handwerger; K B Elkon; C S Via
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

3.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

4.  Natural killer cells and interferon responses in patients with systemic lupus erythematosus.

Authors:  G C Tsokos; A H Rook; J Y Djeu; J E Balow
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

5.  Inhibition of soluble antigen-induced T cell proliferation by warm-reactive antibodies to activated T cells in systemic lupus erythematosus.

Authors:  A Yamada; J B Winfield
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.